Abstract: Objective To investigate the safety and efficiency of intravenous iron dextran in patients on peritoneal dialysis. Methods Fifty-nine patients on peritoneal dialysis were involved in this eight-week, randomized, controlled trial. Twenty-five patients received intravenous iron dextran(IID) and 25 received ferrous succinate(FS). Levels of serum ferritin(SF), transferrin saturation(TSAT), hemoglobin(Hb) and hematocrit(Hct) were tested before and after the treatment. Results After the treatments, the levels of Hb, Hct, SF and TSAT were all significantly increased in IID group, which were also significantly higher than those in FS group. The levels of serum albumin and potassium elevated significantly in IID group, but no obvious changes of above both indexes found in FS group. Seven cases in FS showed adverse gastrointestinal effects. The rate of side-effect in IID(8.0%) was significantly lower than that in FS group(2.8%, P＜0.01). Conclusion Intravenous iron dextran can effectively increase serum iron parameters and hemoglobin levels in peritoneal dialysis patients, with relatively high safety.

Key words: Anemia, Iron-dextran complex